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Abstract
Introduction: Recent studies indicate that bone marrow stromal cells (BMSCs) derived from patients with multiple myeloma
(MM) differ from those of healthy donors in their expression of extracellular matrix compounds and in cytokine production.
It is not known whether these abnormalities are primary or are acquired by BMSCs on contact with MM cells. 
Materials and Methods: Interleukin (IL)-6, IL-11, IL-10, and tumor necrosis factor (TNF)-α production by CD166+ mes-
enchymal BMSCs and the CD38+/CD138+ RPMI8226 myeloma cell line cultivated in vitro in monocultures or co-cultivated
under cell-to-cell contact or non-contact conditions in the presence of a tissue culture insert were measured. Intracellular
cytokines were measured by flow cytometry analysis as the percentage of cytokine-producing cells or by mean fluorescence
intensity as the level of cytokine expression in cells. Additionally, ELISA was used to measure IL-6, soluble IL-6 receptor
(sIL-6R), IL-11, IL-10, TNF-α, B-cell-activating factor of the TNF family (BAFF), hepatocyte growth factor (HGF), and
osteopontin (OPN) production in the supernatants of the cultures and co-cultures.
Results: A higher ability of the BMSCs of MM patients than in controls was detected to produce IL-6, IL-10, TNF-α, OPN,
and especially HGF and BAFF in response to the RPMI8226 cells. Moreover, the BMSCs of the MM patients significantly
enhanced the production of sIL-6R by the RPMI8226 cells.
Discussion: Cytokines over-expressed by BMSCs of MM patients can function as growth factors for myeloma cells (IL-6, 
IL-10, HGF), migration stimulatory factors for tumor plasma cells (TNF-α, HGF), adhesion stimulatory factors (HGF,
BAFF and OPN), stimulators of osteoclastogenesis (IL-6, TNF-α), and angiogenic factors (TNF-α). The results of this
experiment strongly suggest that the BMSCs from MM patients differed in spontaneous and myeloma cell-induced produc-
tion of cytokines, especially of HGF and BAFF, and these abnormalities were both primary and acquired by the BMSCs on
contact with the MM cells. This in turn suggests the presence of an undefined, autocrine stimulation pathway resulting in
a prolonged production of cytokines even in long-term cultures in vitro and in vivo. These abnormalities might provide opti-
mal conditions for the proliferation and differentiation of residual tumor cells or their precursors in the affected bone
marrow.
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INTRODUCTION
Multiple myeloma (MM) is an uncontrolled growth
of cells with the phenotype of terminally differentiated
B cells (plasma cells). The disease usually occurs in the
bone marrow (BM) and is associated with skeletal
pathology, which in most patients appears as multiple
lytic bone lesions and general osteoporosis [36]. 
The BM environment contains a complex reticulum
of extracellular matrix and nonhematopoietic cells, main-
ly of mesenchymal origin, which provides support for the
growth, proliferation, and differentiation of hematopoiet-
ic stem cells and their progeny. Bone marrow stromal
cells (BMSCs) have been shown to provide efficient sup-
port for MM cell survival and proliferation by producing
a high level of interleukin (IL)-6, amajor MM cell growthfactor [51]. Through interaction with BMSCs, MM cells
also stimulate the production of cytokines which support
osteoclastogenesis and angiogenesis [14]. On the other
hand, the impaired osteoblastic function in MM may be
a consequence of a direct action on osteoblasts, since
MM cells enhance their apoptosis [40], and a result of
their differentiation by DKK-1 produced by MM cells
[45]. MM cells also stimulate the production of osteo-
clast-activating cytokines, such as IL-1, tumor necrosis
factor (TNF)-α, and a TNF family member, the receptor
activator of nuclear factor κB ligand (RANKL). In con-
trast, osteoprotegerin, a decoy receptor of RANKL is
down-regulated. In MM, the high RANKL/osteoprote-
gerin ratio leads to an increased number of osteoclasts
and enhanced bone resorption [34]. 
Recent studies indicate that BMSCs in MM patients
differ from those of healthy donors as they express less
CD106 (VCAM-1) and fibronectin and several times
more IL-1β and TNF-α and have an abnormal synthesis
of hyaluronan [4, 5, 13, 48, 49]. A gene expression pro-
file analysis revealed that among 145 distinct genes dif-
ferentially expressed in MM and normal BMSCs there
were genes encoding IL-6 and DKK-1, already known to
be implicated in the pathophysiological features of MM,
as well as new ones, such as GDF-15, a divergent mem-
ber of the TGF-β superfamily involved in angiogenesis,
osteogenic differentiation, or tumor growth [7]. BMSCs
from MM patients also exhibited a reduced efficacy to
inhibit T-cell proliferation compared with normal cells.
These properties existed in the absence of MM cells and
were not associated with the chromosome aberration
that features in tumor plasma cells [1]. 
What is not known is whether these abnormalities
are primary or are acquired by BMSCs on contact with
MM cells. To address this question we conducted stud-
ies on the cytokine production by BMSCs, mainly of
mesenchymal origin, derived from MM patients and
compared it with that of BMSCs derived from control
subjects. Since interactions of MM cells with BMSCs are
important in the disease development, as they stimulate
the production of several cytokines, we also measured
cytokine production by the BMSCs after contact with
the myeloma cell line RPMI8226. 
MATERIALS AND METHODS
Patients
Bone marrow samples of 16 patients with newly diag-
nosed MM and 11 healthy control subjects were obtained
with the patients’ and controls’ written informed consent.
The study was approved by the local ethics committee.
The characteristics of the subjects are shown in Table 1.
Cells
Bone marrow from the patients and the controls was
obtained by sternal puncture. Anti-coagulated BM sam-
ples were diluted 1:2 with Iscove’s Modified
Dulbecco’s medium (IMDM; Gibco, BRL, UK) con-
taining 0.2% methylcellulose (Sigma, St. Louis, MO,
USA). After sedimentation of erythrocytes (30–40 min)
at room temperature, supernatants were collected,
washed twice with IMDM supplemented with 2% fetal
bovine serum (FBS; Gibco), and resuspended in IMDM
supplemented with 10% FBS, 10% horse serum
(Gibco), 1 µM hydrocortisone (Sigma) and 1% antibiot-
ic-antimycotic solution (Gibco). Cells from the super-
natants were seeded in T25 cell culture flasks (Nunc,
Roskilde, Denmark) at a density of 2×106 cells/ml. The
cultures were incubated for 4 weeks at 37°Cin a humid-
ified atmosphere containing 5% CO2. After one week of
incubation, the cultures were semi-populated and non-
adherent cells were respirated together with half of the
medium volume. After 2 and 3 weeks of incubation all
the non-adherent cells were removed together with the
medium. After 4 weeks of incubation a continuous net-
work of adherent cells occupying the entire bottom of
each flask was obtained and adherent cells were treated
with 0.25% trypsin (Sigma) and frozen in IMDM medi-
um supplemented with 20% FBS and 10% DMSO at
–80°C until use. After thawing, the cells were propagat-
ed in T75 flasks in IMDM medium supplemented with
10% FBS. After trypsinization the BMSCs were sus-
pended in IMDM medium with 10% FBS and seeded at
a density of 2×105 cells/ml into six-well plastic plates
(Nunc; 3 ml/well) with a final density of 6×105
BMSCs/well. After 24 h of incubation the supernatants
were removed and new IMDM medium supplemented
with 2% FBS was added.
Cytokine induction
The cultures were divided into three batches. The
first batch of cultures consisted of BMSCs seeded on six-
-well plastic plates and served as a control of sponta-
neous cytokine production by BMSCs. Into the second
batch of BMSCs, myeloma RPMI8226 cells (ECACC
87012702) were added at a density of 1×106 cells/ml in
3 ml of IMDM medium supplemented with 2% FBS
(direct cell-to-cell contact) at a final density of 3×106
cells/well. In the third batch of wells, with a monolayer
of BMSCs, RPMI8226 cells were seeded into tissue cul-
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Table 1. Clinical characteristics of the MM patients and con-
trol subjects
MM Controls
n=16 n=11
Age (mean ±SD) 63.6±9.9 60.9±8
Age (range) 49–83 51–73
Men/women (n) 8/8 4/7
Disease stage acc. to Durie  4/5/7 –
and Salmon [9] I/II/III
% of plasma cells in BM  25.45±17.74 –
(mean ±SD)
Osteolysis 0/1/2/3 3/1/3/9 –ture inserts (Transwell; Costar, Cambridge, MA, USA)
with a pore diameter of 0.4 µm. After 18 h of co-culture
incubation, brefeldin (a protein transport inhibitor) at
a concentration of 10 µg/ml was added and the co-cul-
tures were incubated for an additional 4 h at 37°C. The
supernatants of the cultures and co-cultures were col-
lected and stored at –80°C until cytokine measurement
by ELISA. The cells were washed with PBS (without
Ca2+ and Mg2+), trypsinized, resuspended in PBS, and
subjected to flow cytometric analysis. Another batch of
six-well plastic plates with co-cultures of BMSCs with
RPMI8226 cells were incubated for 72 h at 37°C and the
cytokine concentrations in the supernatants were mea-
sured by ELISA.
Assay for cytokines
The concentrations of IL-10, IL-11, B-cell-activating
factor of the TNF family (BAFF)/BlyS, osteopontin
(OPN), and hepatocyte growth factor (HGF) were mea-
sured by ELISA using commercially available kits from
R&D Systems, Minneapolis, MN, USA. The detection
limits were 3.9 pg/ml for IL-10, 8 pg/ml for IL-11,
0.73–6.67 pg/ml for BAFF, 0.006–0.024 ng/ml for OPN,
and 40 pg/ml for HGF. The concentrations of TNF-α,
IL-6, and soluble IL-6 receptor (sIL-6R) were measured
by ELISA using kits from Bender MedSystems, GmbH,
Vienna, Austria. The detection limits were 3.83 pg/ml
for TNF-α, 0.92 pg/ml for IL-6, and 0.01 ng/ml for 
sIL-6R. 
Intracellular cytokine staining
Reagents. Monoclonal antibodies (moAb) anti-CD38
PE-Cy5 (clone: HIT2, isotype: IgG1) and CD138 FITC
(clone: Mi15, isotype: IgG1) were obtained from BD
PharMingen (San Diego, CA, USA). The CD14 TRI-
-Color(clone: Tük4, isotype: IgG2a) moAb was obtained
from Caltag Laboratories (Burlingame, CA, USA). Anti-
-CD166 FITC (clone: 3A6, isotype: IgG1) was obtained
from Ancell (Bayport, MN, USA). PE-conjugated moAb
anti-TNF (clone: MAb11, isotype: IgG1), anti-IL-6
(clone: MQ2-6A3, isotype: IgG2a), and anti-IL-10 (clone:
JES3-19F1, isotype: IgG2a) were purchased from BD
PharMingen. Anti-IL-11 PE (clone: 22626, isotype:
IgG2a) was obtained from R&D Systems (Minneapolis,
MN, USA). Mouse IgG1 and rat IgG2a isotype controls
were obtained from BD PharMingen. IntraPrepTM was
purchased from Immunotech (Marseille, France).
Sample staining. The cultured cells were washed
twice in PBS, divided into tubes at a concentration of
5×105 cells per tube, and then stained with moAb
against the cell-surface markers CD138, CD38, and
CD166 (20 min at room temperature). Following mem-
brane staining, the cells were fixed and permeabilized
with the IntraPrep kit according to the manufactur-
er’s instructions. Then the cells were incubated with
anti-TNF, anti-IL-6, anti-IL-10, and anti-IL-11 moAb or
an appropriate isotype control for 15 min at room tem-
perature. Finally, the cells were washed and analyzed by
flow cytometry directly after preparation.
Flow cytometric analysis
The samples were analyzed by two- and three-color
flow cytometry using a Becton Dickinson FACS-Calibur
instrument. For the analysis of CD38+/CD138+ cells
staining for intracellular cytokine expression, five data
parameters were acquired and stored: linear forward
and side scatter (FSC, SSC), green fluorescence (FL-1),
orange-fluorescence (FL-2), and red-fluorescence (FL-3).
For each analysis, 10,000 events were acquired and ana-
lyzed using CellQuest software. An acquisition gate was
established based on FSC and SSC that excluded dead
cells and debris (Fig. 1a). The R1-gated events were
analyzed for CD38+/CD138+ staining (Fig. 1b) and pos-
itive cells were selected (region R2). Dot plots of CD38
PE-Cy5 vs. CD138 FITC were used. The final dot plots,
i.e. CD38 PE-Cy5/isotype control (Fig. 1c) and CD38
PE-Cy5/anti-cytokine moAb PE (Fig. 1d), were estab-
lished by combined gating of events using R1 and R2.
An isotype-matched antibody was used to verify the
staining specificity and as a guide for setting the mark-
ers to delineate positive and negative populations.
For the analysis of CD166+ cells staining for intracel-
lular cytokine expression, four data parameters were
acquired and stored: FSC, SSC, FL-1, and FL-2. An acqui-
sition gate was established based on FSC and SSC (region
R1; Fig. 2a). Then the R1-gated events were analyzed for
CD166 FITC staining and positive cells (CD166+) were
gated (R2; Fig. 2b). The dot plots CD166 FITC versus an
isotype control (Fig. 2c) and CD166 FITC versus an
appropriate anti-cytokine moAb PE (Fig. 2d) were estab-
lished by combined gating of events using R1 and R2.
In the experiment, the mean percentage of cells with
intracellular cytokine expression and the level of
cytokine expression in cells indicated by mean fluores-
cence intensity (MFI) were analyzed. MFIis the average
fluorescence intensity of all analyzed cells.
Statistics
Results are reported as the mean ±SD. The signifi-
cance of differences was determined with the use of
analysis of variance (STATISTICA computer package).
A number of statistical tests were used, including the two-
-way ANOVA test with post-hoc Tukey’s test to measure
the differences within a group and the Mann-Whitney 
U-test to measure the differences between groups. The
concentrations of cytokines below the detection level
were considered to be 0 for the purpose of the analysis.
p values of 0.05 or less were considered significant.
RESULTS
The BMSCs were selected by their adherence to
plastic vessels. The cells were obtained from 16 MM
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Fig. 1. The dot plots show representative data from one patient illustrating the method for the iden-
tification of CD38+/CD138+ cells expressing IL-11 following three-color staining. The cells were
gated (R1) using FSC and SSC plots (a). Then the R1-gated events were analyzed for
CD38+/CD138+ staining and positive cells were selected (region R2). We used a dot plot of CD38
PE-Cy5 vs. CD138 FITC (b). The final dot plots: CD38 PE-Cy5/isotype control (c) and CD38 PE-
-Cy5/IL-11 PE (d), were established by combined gating of events using R1 and R2. The number
in the upper right quadrant on dot plot d represents the percentage of CD38+/CD138+/IL-11+
cells. For the analysis shown, the RPMI8226 control was used.
R1
R2
CD166 FITC
CD166 FITC
CD166 FITC
M
o
u
s
e
I
g
G
2
a
P
E
I
L
-
1
1
P
E
a b
c
d
26.19%
R2
R1
Fig. 2. The dot plots show representative data from one patient illustrating the method for the
identification of CD166+ cells expressing IL-11 following two-color staining. The cells were gated
(R1) using FSC and SSC plots (a). Then the R1-gated events were analyzed for CD166+ staining
and positive cells were selected (region R2). We used a dot plot of CD166 FITC vs. SSC (b). The
final dot plots: CD166 FITC/isotype control (c) and CD166 FITC/IL-11 PE (d), were established
by combined gating of events using R1 and R2. The number in the upper right quadrant on dot
plot d represents the percentage of CD166+/IL-11+ cells. For the analysis shown, a co-culture of
CD166+ cells with RPMI8226 CD38+/CD138+ was used. 
patients and 11 control subjects. As BMSC proliferation
is correlated with the age of donors, we had chosen con-
trol donors who were age matched with the MM
patients. The MM and the control BMSCs did not differ
significantly in the percentage of CD166+ (a marker for
human BM stroma fibroblasts [42]) and CD14+ cells
(Table 2). A FACS analysis did not detect
CD38+/CD138+ cells in either case, thus demonstratingthat the BMSC cultures were not contaminated by MM
cells. Moreover, the production of tartrate-resistant acid
phosphatase (TRAP) and alkaline phosphatase was also
comparable between the BMSCs from the MM patients
and the controls, indicating that there were no signifi-
cant differences in TRAP-positive cells or osteoblast
precursors between the BMSC cultures. 
The aim of this study was to investigate the differ-
ences in cytokine production between BMSCs isolated
from MM patients and those of control subjects. When
the level of IL-6 was measured by ELISA (Fig. 3A), only
BMSCs of MM patients cultivated under non-contact
conditions with RPMI8226 cells produced more IL-6
than controls. To verify this finding, the level of IL-6 was
additionally measured by flow cytometry in which the
percentage of cells with the intracellular cytokine or the
MFI level of cytokine expression was estimated in
CD166+ (of both controls and MM patients) and
CD38+/CD138+ myeloma RPMI8226 cells (Fig. 3C, D,
E, F). When the percentage of cells expressing IL-6 was
measured by flow cytometry, mesenchymal CD166+
cells of the MM patients produced significantly more
IL-6 in response to RPMI8226 cells than controls, espe-
cially when the cells were separated by a porous mem-
brane. Moreover, IL-6 was also produced by
CD38+/CD138+ myeloma cells, especially when they
were in direct contact with BMSCs. The BMSCs of the
MM patients stimulated CD38+/CD138+ plasma cells to
produce IL-6 in direct contact more efficiently than the
BMSCs of controls. Moreover, MFI indicated a higher
ability of the BMSCs from the MM patients to produce
IL-6 spontaneously and after contact with RPMI8226
cells, though these differences were not statistically sig-
nificant. However, when the sum of IL-6-producing
CD166+ and CD38+/CD138+ cells was calculated, the
sum was highest when the cells were in direct cell-to-cell
contact. Such an unexpected difference between the
results received from ELISA and cytometric analysis
prompted us to measure the level of sIL-6R. We sus-
pected that sIL-6R, which can bind IL-6, might have
been the reason why IL-6 was not detected by the
ELISA kit. The results presented in Fig. 3B indicated
a very high level of sIL-6R, mainly produced by
RPMI8226 in monocultures and in co-cultures with the
BMSCs of controls and MM patients. The BMSCs in
monocultures did not produce any sIL-6R. Moreover,
sIL-6R expression was highest when the BMSCs and the
RPMI8226 cells were cultivated together. Therefore it
seems likely that the formation of a complex between
sIL-6R and IL-6, not detected by the ELISA kit, was
indeed the cause of the differences in the results
obtained by the different methods. 
When IL-11 production was examined by the ELISA
method, no statistically significant differences between
the controls and the MM group was observed (Fig. 4A).
The RPMI8226 cells produced a low but detectable
level of IL-11. Cytometric analysis revealed that the
RPMI8226 cells were the main producer of IL-11, espe-
cially after direct contact with the BMSCs of the MM
patients (Fig. 4C). There were no significant differences
in IL-11 production between the BMSCs derived from
the BM of controls and MM patients.
In ELISA, both the spontaneous production of IL-
-10 by the BMSCs of the MM patients and, especially, its
production after cell-to-cell contact with the RPMI8226
cells were significantly higher in the MM group than in
the controls (Fig. 5). The percentage of IL-10-producing
cells in the BMSCs estimated by cytometric analysis was
highest when the BMSCs of the MM patients were sep-
arated from the RPMI8226 cells by a porous membrane.
The RPMI8226 cells also expressed IL-10 when they
were in cell-to-cell contact with the BMSCs of the
myeloma patients. The sum of the percentages of the
IL-10-producing BMSCs of the MM patients and
RPMI8226 cells was highest when the cells were culti-
vated in cell-to-cell contact conditions. MFI analysis
revealed that the BMSCs of the MM patients expressed
more IL-10 spontaneously, without contact with the
RPMI8226 cells, than the control BMSCs, confirming
the results obtained by ELISA.
The ELISA of TNF-α revealed that the BMSCs of
the MM patients produced more TNF-α after direct
contact with the RPMI8226 cells than did the control
BMSCs. It should be noted that there were great differ-
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Table 2. Characteristics of the BMSCs derived from MM patients and control subjects
Parameter MM patients Controls
n=16 n=11
MoAb CD38+/CD138+ (% of positive cells) 0 0
MoAb *CD166+ (% of positive cells) 75.60±11.95 86.6±8.5
MoAb CD14+ (% of positive cells) 13.1±6.0 9.8±9.1
TRAP (µmol of pNP/1×105 cells) 33.7±3.0 44.9±16.4
ALP (µmol of pNP/ 1×105 cells) 45.78±12.20 38.47±14.35
*Marker for human BM stroma fibroblast [42].
Cells were analyzed by three-color flow cytometry using MoAb anti-CD38 PE-Cy5 and CD138 FITC, CD14 Tri-Color, and
CD166 FITC using a Becton Dickinson FACS-Calibur.
Tartrate-resistant acid phosphatase (TRAP) was measured by microplate colorimetric assay according to the method described by
Nakasato et al. [31].
Alkaline phosphatase (ALP) activity was measured by colorimetric assay as described by Coelho and Fernandez [6].ences in the ability of the BMSCs of MM patients to
produce TNF-α, resulting in very high standard devia-
tions. The percentage of TNF-α-producing cells mea-
sured by flow cytometry was significantly higher in the
BMSCs derived from the MM patients compared with
controls when they were separated from the myeloma
RPMI8226 cells by a transwell (Fig. 6). The RPMI8226
cells also produced more TNF-α when they were in cell-
-to-cell contact with the BMSCs of the MM patients.
MFI analysis revealed that the expression of TNF-α on
cells was higher in the BMSCs of the MM patients than
in those of the controls, but these differences were not
statistically significant because of the high standard
deviation values. 
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Fig. 3. Production of IL-6 in cultures and co-cultures of BMSCs of MM patients and control subjects with RPMI8226 myeloma cells.
Production of IL-6 was measured by ELISA (A) and by cytometric analysis in monocultures of CD166+ cells (markers for mesenchymal stro-
mal fibroblasts), monocultures of CD38+/CD138+ myeloma cells, and in co-cultures where both types of cells were in direct cell-to-cell con-
tact (direct) or were separated by a transwell (non-contact). The level of IL-6 expression was measured by flow cytometry as the percentage
of IL-6-expressing cells (C, D) or as the MFI (E, F), indicating the level of IL-6 expression in cells. Moreover, production of sIL-6R was mea-
sured by ELISA (B). *Significantly different from the control group, p<0.05; #significantly different from monoculture within the group,
p<0.05.
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A BWhen the production of BAFF was measured by
ELISA in the supernatants of the BMSC and
RPMI8226 cultures and co-cultures, it was found that
the BMSCs of the MM patients produced significantly
more BAFF than control BMSCs (Fig. 7A). The
amounts of BAFF produced by the BMSCs of the MM
patients varied significantly, which resulted in a very
high standard deviation; however, no correlations with
the stage of the disease or the intensity of bone lesions
were observed. Direct cell-to-cell contact of the BMSCs
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Fig. 4. Production of IL-11 in cultures and co-cultures of BMSCs of MM patients and control subjects with RPMI8226 myeloma cells was
measured by ELISA (A) or by cytometric analysis in monocultures of CD166+ cells (markers for mesenchymal stromal fibroblasts), mono-
cultures of CD38+/CD138+ myeloma cells, and in co-cultures where both types of cells were in direct cell-to-cell contact (direct) or were
separated by a transwell (non-contact). The level of IL-11 expression in cells was measured by flow cytometry as the percentage of IL-11- 
-expressing cells (B, C) or as the MFI (D, E), indicating the level of IL-11 expression in cells. #Significantly different from monoculture with-
in the group, p<0.05.
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BAFF production. The RPMI8226 cells cultivated alone
did not release BAFF into the culture medium. 
The production of HGF was measured by ELISA
(Fig. 7B). There were significant differences in the
amounts of HGF released into the culture medium from
the BMSCs of the MM patients and those of the con-
trols. Especially after 72 h of incubation, significantly
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Fig. 5. Production of IL-10 in cultures and co-cultures of BMSCs of MM patients and controls with RPMI8226 myeloma cells. Production
of IL-10 was measured by ELISA (A) or by cytometric analysis in monocultures of CD166+ cells (markers for mesenchymal stromal fibrob-
lasts), monocultures of CD38+/CD138+ myeloma cells, and in co-cultures where both types of cells were in direct cell-to-cell contact (direct)
or were separated by a transwell (non-contact). The level of IL-10 expression was measured by flow cytometry as the percentage of IL-10-
-expressing cells (B, C) or as the MFI (D, E), indicating the level of IL-10 expression in cells. *Significantly different from control group,
p<0.05; #significantly different from monoculture within the group, p<0.05.
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*higher amounts of HGF were present in the media of
the BMSCs of the MM patients than in those of the con-
trols. A very slight, not statistically significant, enhance-
ment of HGF production after co-culture of the
RPMI8226 cells with the BMSCs was observed. The
RPMI8226 cells cultivated alone produced very low lev-
els of HGF. 
ELISA measurements of OPN released into the cul-
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Fig. 6. Production of TNF-α in cultures and co-cultures of BMSCs of MM patients and controls with RPMI8226 myeloma cells. Production
of TNF-α was measured by ELISA (A) or by cytometric analysis in monocultures of CD166+ cells (markers for mesenchymal stromal fibrob-
lasts), monocultures of CD38+/CD138+ myeloma cells, and in co-cultures, where both types of cells were in direct cell-to-cell contact (direct)
or were separated by a transwell (non-contact). The level of TNF-α expression was measured by flow cytometry as the percentage of TNF-
-α-expressing cells (B, C) or as the MFI (D, E), indicating the level of TNF-α expression in cells. The level of TNF-α was also measured by
ELISA (E). *Significantly different from the control group, p<0.05; #significantly different from monoculture within the group, p<0.05.
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#ture medium revealed that the BMSCs of the MM
patients and of the controls produced very low amounts
of OPN (Fig. 7C). In contrast, the RPMI8226 cells pro-
duced high amounts of OPN. Additionally, the level of
OPN increased after co-culture of the BMSCs with the
RPMI8226 cells both in direct cell-to-cell contact and in
the presence of a culture insert. Moreover, co-cultures
of the BMSCs of the MM patients with the RPMI8226
cells produced more OPN than those of the control
BMSCs. 
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Fig. 7. Production of BAFF (A), HGF (B), and OPN (C) in cultures of BMSCs of MM patients and control subjects and in co-cultures of
both types of cells cultivated in cell-to-cell contact or in non-contact conditions, where the cells were separated by a transwell. The cytokine
level was measured by ELISA in supernatants from the monocultures and co-cultures. *Significantly different from the control group,
p<0.05; #significantly different from monoculture within the group, p<0.05.
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#Table 3 lists the correlations between the cytokines
expressed in CD166+ cells and CD38+/CD138+
(RPMI8226) cells. It can be seen that the production of
IL-6 correlated positively with several cytokines pro-
duced both in the BMSCs of the MM patients and in the
myeloma cell line.
DISCUSSION
There is growing evidence for the existence of a net-
work of cytokines operating in the growth, progression,
and dissemination of MM [25]. Among the numerous
growth and survival factors for myeloma cells, IL-6 is con-
sidered the most important and is the best characterized. 
The induction of IL-6 in BMSCs from myeloma
patients and normal donors by myeloma tumor cell lines
has already been described by other authors [28]. It has
been found that BMSCs of MM patients produce more
IL-6 than those of healthy controls. While some authors
stressed that direct contact between the two types of
cells was necessary for this induction, others [2] found
that a significant increase in IL-6 concentration
occurred when the myeloma cells (isolated from
patients or myeloma-derived cell lines) were co-cultured
with BMSCs of MM patients in a non-contact transwell
system. The latter authors suggested that this was
caused by bFGF expressed by myeloma cells which
bound with bFGF receptors on BMSCs and thus stimu-
lated IL-6 production. These data demonstrate that
paracrine interactions between myeloma cells and
BMSCs trigger the stimulation of IL-6. In our study we
also established that direct binding of plasma cells to
BMSCs is not prerequisite for the induction of IL-6.
When the RPMI8226 cells were separated from the
BMSCs by a tissue culture insert which prevented direct
cellular contact but allowed an exchange of soluble fac-
tors, IL-6 was also produced by both the BMSCs and the
myeloma cells. These observations are in agreement
with the results of other authors [12] who found that IL-6
could be produced in response to soluble factors, pro-
duced mainly by myeloma cells, such as RANKL, IL-1β,
TNF-α, and TGF-β and cytokines produced by BMSCs,
such as VEGF and HGF [8, 26]. These results suggest
that in vivo not only myeloma cells attached to stroma,
but also unattached cells may autocrinely produce IL-6.
In our study we also discovered, for the first time in the
literature, that direct contact of BMSCs of MM patients
with RPMI8226 myeloma cells induces overproduction
of sIL-6R. As sIL-6R is known to form a complex with
IL-6, and such complexes can bind to gp130 even on
cells which lack membrane-bound IL-6R and trigger
gp130 cellular signaling [39], it seems likely that the
effect of IL-6 overproduction by BMSCs of MM
patients can have more pronounced consequences than
that expected from IL-6 overproduction itself. 
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Table 3. Correlations between cytokines produced by the CD166+ cells of MM patients and CD38+/CD138+ RPMI 8226 cells
measured by MFI (flow cytometric analysis)
Cytokine R p
CD166+cells of MM patients (monoculture) IL-6 vs. IL-10 +0.96 0.000002
IL-6 vs. IL-11 +0.61 0.042
IL-6 vs. TNF-α +0.86 0.0006
IL-10 vs. TNF-α +0.79 0.003
IL-11 vs. TNF-α +0.63 0.03
CD166+ cells (direct contact with MM cells) IL-6 vs. IL-10 +0.86 0.0006
IL-6 vs. TNF-α +0.91 0.0001
IL-10 vs. TNF-α +0.8 0.003
CD166+ cells (separated by a transwell from MM cells) IL-6 vs. IL-10 +0.73 0.025
IL-6 vs. TNF-α +0.98 0.000004
IL-10 vs. TNF-α +0.78 0.01
CD38+/138+ cells (monoculture) IL-6 vs. IL-10 +0.95 0.000000
IL-6 vs. IL-11 +0.55 0.025
IL-6 vs. TNF-α +0.91 0.000001
IL-10 vs. TNF-α +0.93 0.000000
IL-11 vs. TNF-α +0.051 0.039
CD38+/138+ cells (direct contact with stromal cells  IL-6 vs. IL-10 +0.96 0.000002
of MM patients) IL-6 vs. TNF-α +0.89 0.0005
IL-10 vs. TNF-α +0.83 0.0029
CD38+/138+ cells (separated by a transwell  IL-6 vs. IL-10 +0.93 0.0002
from stromal cells of MM patients) IL-6 vs. IL-11 +0.83 0.005
IL-6 vs. TNF-α +0.85 0.006
IL-10 vs. IL-11 +0.85 0.003
IL-10 vs. TNF-α +0.78 0.02
IL-11 vs. TNF-α +0.72 0.046IL-6 is a member of the IL-6 family of cytokines,
which includes, among others, IL-11, that commonly use
gp130 as a signal transducing molecule. IL-6 and IL-11
have both been reported to stimulate myeloma cell
growth [19]. Both are also known to promote osteoclas-
togenesis and bone resorption in BM cultures [11, 24]. It
has already been found that in a co-culture system of
BMSCs of MM patients with a human myeloma cell
line, plasma cells upregulate IL-11 secretion by BMSCs
through cell-to-cell contact [12]. In our experiments,
a cytometric analysis confirmed that direct cell-to-cell
contact significantly enhanced IL-11 production,
although more efficiently in the RPMI8226 cells than in
the BMSCs. It also showed that in co-cultures, the
RPMI8226 cells were the main source of IL-11. In our
experiments, however, there were no significant differ-
ences between the BMSCs from myeloma patients and
controls in the ability to produce IL-11. 
IL-10 is the most potent B cell differentiation factor.
It can also stimulate the proliferation of myeloma cells
in IL-6-deprived cultures and thus can be regarded as an
IL-6 unrelated growth factor for malignant plasma cells
[32, 33]. It is produced by the myeloma cells of about
half of patients and is detected in the blood of MM
patients. The myeloma cell growth activity of IL-10 is
mediated through a gp130 cytokine, oncostatin
M (OSM), which is frequently produced by myeloma
cells. IL-10 induces receptors for OSM on myeloma
cells [23, 33]. Moreover, IL-10 inhibits osteogenic activ-
ity in mouse BM, and may thus also be involved in bone
lytic lesions in MM [47]. The high expression of IL-10
which we detected in unstimulated BMSCs of MM
patients confirms our previous observations [50] and
strongly suggests that the overproduction of IL-10 by
stromal cells may function as a microenvironmental fac-
tor in BM promoting residual myeloma cell growth even
in patients in remission. It should be noted that IL-10
overexpression induced by direct cell-to-cell contact of
BMSCs with RPMI8226 cells was described by us for the
first time in the literature. 
In the BM, TNF-α is produced not only by the cells
of the BM stroma, but also by myeloma cells themselves
[37]. TNF-α has been shown to act as a survival factor
for myeloma cells [21] and, in combination with IL-4, to
be implicated in myeloma precursor cell differentiation
[38]. Moreover, TNF-α is able to trigger the secretion of
IL-6 from BMSCs [15, 44] and displays proangiogenic
properties [10]. It has been observed that BM cells
explanted from MM patients produce higher amounts
of TNF-α than those of comparable controls. The extent
of production correlated with the stage of disease, espe-
cially with the presence of extensive osteolytic bone dis-
ease [27]. Furthermore, TNF-α enhanced the trans-
endothelial migration of myeloma cells [20]. In our
experiment, TNF-α was produced mainly by the BMSCs
of MM patients under non-contact and cell-to-cell con-
tact conditions in the presence of RPMI8226 cells, but
the differences between the BMSCs from MM patients
and controls were not striking. However, the RPMI8226
cells also produced TNF-α, especially after direct cell-
-to-cell contact with the BMSCs of MM patients.
Most recently, the BAFF of the TNF family pro-
duced by myeloid cells was identified as a critical factor
in normal B-cell development and homeostasis. It is
expressed predominantly by macrophages and dendritic
cells in both membrane-bound and proteolytically
cleaved soluble protein [29]. BAFF was detected in
myeloma cells and in sera derived from MM patients,
suggesting an autocrine loop of stimulation from the
tumor cells. However, the biological role of BAFF in
myeloma pathogenesis has not been fully characterized.
It has been revealed that BAFF is present on BMSCs
derived from MM patients and its secretion is higher in
BMSCs than in myeloma cells. Moreover, tumor cell
adhesion to BMSCs augments BAFF secretion [43]. In
our experiment we detected using ELISA that
RPMI8226 cells without contact with BMSCs did not
produce BAFF, whereas the BMSCs of MM patients
spontaneously produced high amounts of BAFF, which
did not increase after co-culture with the myeloma cells.
Our results are not in agreement with the results of
other authors [43], mentioned above, which indicate
that adhesion of myeloma cells to BMSCs augments
BAFF production. These discrepancies may be due to
the fact that different myeloma cells were used for the
experiments. Tai et al. [43] used purified CD138+
myeloma cells isolated from patients which, as described
by other authors [30], did not express BAFF-R, but
expressed B-cell-maturating antigen (BCMA), another
BAFF receptor. In contrast to that, RPMI8226 cells
were described to express three BAFF receptors:
BCMA, BAFF-R, and TACI (transmembrane activator
and calcium modulator and cyclophilin ligand receptor).
Therefore, in our experiment BAFF could have been
bound to the surface receptors on RPMI8226 cells and
removed from the culture media. Moreover, Moreaux et
al. [30] reported that BMSCs, in contrast to osteoclasts,
are poor producers of BAFF. In our BMSC cultures,
CD14+ cells were detected, which can be precursors of
osteoclasts. Therefore it cannot be excluded that CD14+
producing cells were the main source of BAFF. On the
other hand there were no differences in the number of
CD14+ cells between the controls and the MM group, so
the question why the BMSCs of the MM patients pro-
duced more BAFF than those of the controls needs fur-
ther experiments.
Recent studies have identified HGF as a potential
key signal in the evolution of MM as HGF exerts
a strong proliferative and antiapoptotic effect on myelo-
ma cells by way of the RAS/MAPK and PI3K/PKB path-
ways. BMSCs producing HGF are a paracrine source of
HGF, but myeloma cells are a source of HGF as well.
Moreover, myeloma cells catalyze HGF activation by
secreting an activator of HGF [46]. In our experiments,
however, we showed that RPMI8226 myeloma cells cul-
tivated alone produced a very low level of HGF. These
results are not in agreement with the results reported by
Borset et al. [3], who did detect production of HGF by
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to differences in the culture conditions, such as the time
of incubation and the culture medium used, with 10% of
FBS in Borset’s experiment and 2% of FBS in our
experiment. In contrast to the poor secretion of HGF by
RPMI8226, we found that BMSCs of myeloma patients
are a rich source of HGF. These results are in agree-
ment with earlier publications indicating a high produc-
tion of HGF by BM cells of MM patients [16, 22]. It was
recently found that HGF enhances myeloma cell adhe-
sion to the BM matrix protein fibronectin [17] and plays
an important role in the proliferation, adhesion, and
migration of myeloma cells [18]. The spontaneous over-
production of HGF by BMSCs of MM patients, even in
the absence of myeloma cells, strongly suggests that the
BM microenvironment of persons with MM may
enhance the proliferation and dissemination of myelo-
ma cells residual after chemotherapy. 
OPN is a multifunctional protein that promotes cell
adhesion and migration, inhibits hydroxyapatite forma-
tion, and binds Ca2+ [35]. OPN is strongly associated
with tumorgenesis. In patients with MM, plasma levels
of soluble OPN are associated with poor prognosis.
Multiple myeloma cells adhere to OPN, which implies
that elevated stromal expression of OPN may be one of
the factors responsible for the retention of myeloma
cells in the BM. Elevated plasma OPN levels in MM
patients could be due both to the production of OPN by
tumor cells and to tumor-induced production of OPN by
non-tumor cells [41]. In our experiments we confirmed
that OPN can be produced by myeloma cells. Moreover,
we discovered that OPN production in co-cultures of
the BMSCs from myeloma patients with RPMI8226
cells is significantly higher than in respective co-cultures
of control BMSCs with myeloma cells. We do not know
whether BMSCs or RPMI8226 cells are the producers
of OPN, but these results strongly suggest that either the
BMSCs of MM patients produce more OPN or they
more effectively support OPN production by myeloma
cells. 
Summing up, we detected a high ability of BMSCs of
MM patients, in comparison with controls, to produce
IL-6, IL-10, TNF-α, and OPN in response to RPMI8226
cells. However, the differences in their production by
the BMSCs of MM patients and of controls were not
striking. In contrast, the production of HGF, BAFF, and
sIL-6R was significantly higher. Cytokines over-
-expressed by the BMSCs of MM patients exhibit sever-
al biological properties and can function as growth fac-
tors for myeloma cells (IL-6, IL-10, HGF), migration
stimulatory factors for tumor plasma cells (TNF-α,
HGF), adhesion stimulatory factors (HGF, OPN), stim-
ulators of osteoclastogenesis (IL-6, TNF-α), and proan-
giogenic factors (TNF-α). Therefore the results of our
experiments strongly suggest that in spite of a lack of
differences in morphology, surface antigen, and enzyme
production between BMSCs from MM patients and
controls, they differ in spontaneous and myeloma cell-
-induced production of cytokines. Interestingly a contin-
ued production of cytokines was observed in the
BMSCs, independent of the long time of in vitro cultiva-
tion (several weeks). This suggests the presence of an
undefined autocrine stimulation pathway resulting in
prolonged production of cytokines in vivo. If these in
vitro findings reflect in vivo behavior, the continued pro-
duction of cytokines, even during disease remission,
might provide optimal conditions for the proliferation
and differentiation of residual tumor cells or their pre-
cursors in the affected BM.
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